PipelineReview.com2d
China’s First IGF-1R Monoclonal Antibody: Innovent Announces NMPA approval of SYCUME® for the Treatment of Thyroid Eye Disease
SAN FRANCISCO, CA, USA and SUZHOU, China I March 14, 2025 I Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company ...
Nature6y
High IGF-I levels imply active acromegaly even when GH levels are 'normal'
Biochemical control of acromegaly in noncured patients is usually defined as serum growth hormone (GH) levels <2.0 µg/l, plus normal-for-age serum levels of insulin-like growth factor I (IGF-I).
BioWorld11d
Lirum’s LX-101 shows potent antitumoral effects in aggressive tumors
Lirum Therapeutics Inc. has presented data regarding their insulin-like growth factor receptor (IGF-1R) antagonist LX-101, which couples an IGF-1 variant to a cytotoxic methotrexate payload. The ...
Morningstar2d
China's First IGF-1R Monoclonal Antibody: Innovent Announces NMPA approval of SYCUME® for the Treatment of Thyroid Eye Disease
a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody) for the treatment of thyroid eye disease (TED). As China's first and the world's second approved IGF-1R antibody drug ...